Related Experiment Video

Updated: Aug 5, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

[Recent advances in the treatment of chronic myeloid leukemia]

Seiichiro Katagiri1

  • 1Department of Hematology, Tokyo Medical University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|August 3, 2026
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) have improved chronic myeloid leukemia (CML) outcomes. This review covers somatic mutations and novel inhibitors, like STAMP inhibitors, for better CML management and treatment resistance.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Tyrosine kinase inhibitors (TKIs) have significantly advanced chronic myeloid leukemia (CML) treatment.
  • ABL myristoyl pocket (AMP) inhibitors offer targeted therapy with reduced adverse events.

Purpose of the Study:

  • To summarize the frequency and clinical impact of somatic mutations in chronic-phase CML (CML-CP).
  • To review novel TKIs and STAMP inhibitors for improved CML management.

Main Methods:

  • Literature review of studies on somatic mutations in CML-CP.
  • Analysis of clinical data regarding treatment resistance and novel therapeutic agents.

Main Results:

  • Somatic mutations in genes beyond ABL1 are increasingly recognized for their role in TKI resistance.
  • Novel TKIs and STAMP inhibitors show promise for overcoming resistance and improving patient outcomes.

Conclusions:

  • Understanding somatic mutations is crucial for managing CML treatment resistance.
  • Emerging therapies like novel TKIs and STAMP inhibitors are expected to enhance future CML treatment strategies.
Keywords:
Chronic myeloid leukemiaSTAMP inhibitorsSomatic mutationsTyrosine kinase inhibitors

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...